学位 【 表示 ／ 非表示 】

学位 【 表示 ／ 非表示 】

• 札幌医科大学   医学博士

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

• ライフサイエンス   腫瘍診断、治療学  

researchmapの所属 【 表示 ／ 非表示 】

researchmapの所属 【 表示 ／ 非表示 】

• 消化器・総合、乳腺・内分泌外科   助教  

• 札幌医科大学   医学部   助教  

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• 癌幹細胞マーカーに対する自己抗体を利用した乳癌患者の予後予測(Prediction of Prognosis in Breast Cancer Patients Using Autoantibodies to Cancer Stem Cell Markers)

  及能 大輔, 廣橋 良彦, 和田 朝香, 島 宏彰, 九冨 五郎, 真柄 和史, 高澤 久美, 高澤 啓, 竹政 伊知朗, 小山内 誠

  日本癌学会総会記事 ( (一社)日本癌学会 )  82回   2116 - 2116  2023年09月

• エリブリンはヒト白血球抗原クラスIのアップレギュレーションによる乳癌の免疫増強因子である(Eribulin is an immune potentiator in breast cancer by up-regulation of human leukocyte antigen class I)

  和田 朝香, 九冨 五郎, 廣橋 良彦, 島 宏彰, 及能 大輔, 空閑 陽子, 鳥越 俊彦, 竹政 伊知朗

  日本乳癌学会総会プログラム抄録集 ( (一社)日本乳癌学会 )  31回   66 - 66  2023年06月

• Positional advantages of supine MRI for diagnosis prior to breast‑conserving surgery.

  Goro Kutomi, Hiroaki Shima, Daisuke Kyuno, Fukino Satomi, Asaka Wada, Yoko Kuga, Minoru Okazaki, Akira Okazaki, Hideji Masuoka, Toshihiko Mikami, Yuichi Yuyama, Takashi Matsuno, Tosei Ohmura, Hidekazu Kameshima, Toru Mizuguchi, Ichiro Takemasa

  Molecular and clinical oncology   18 ( 5 ) 44 - 44  2023年05月  [国際誌]

  　概要を見る

  The present study aimed to evaluate the rate of positive surgical margins for magnetic resonance imaging (MRI) performed in the supine position prior to breast-conserving surgery (BCS). The rate of positive surgical margins and the clinicopathological factors were examined in consecutive patients with BCS who underwent preoperative MRI performed in the supine position at Sapporo Medical University Hospital (Sapporo, Japan) and related hospitals and clinics between January 2012 and December 2013. Of 1,175 eligible patients, 1,150 were included after excluding 25 patients with either bilateral breast cancer or stage IV disease. Positive margin was defined as no cancer seen on the resected margin. The primary endpoint was the rate of positive surgical margins when preoperative MRI was performed in the supine position and the secondary endpoint was identification of the factors that predict positive margins. Of the 1,150 female patients (median age, 55 years; range, 29-97 years) who underwent BCS for breast cancer following MRI performed in the supine position, 215 (18.8%) had positive margins, which is similar to the rate with MRI in the prone position, and 930 (81.2%) had negative margins. The rate of positive surgical margins in patients of the human epidermal growth factor receptor 2 (HER2) type was significantly higher than that in the non-HER2 type group (6.5 and 2.9%; χ2 P=0.0103). There was no increase in the rate of positive margins in breast cancers with a diameter of >T2. The rate of positive surgical margins following MRI performed in the supine position was 18.8%. Supine MRI appears to be suitable for informing on the extent of resection of breast cancer.

  DOI PubMed

• Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy.

  Hiroaki Shima, Goro Kutomi, Yoko Kuga, Asaka Wada, Fukino Satomi, Kiminori Sato, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Hidekazu Kameshima, Tosei Ohmura, Tadashi Hasegawa, Ichiro Takemasa

  Experimental and therapeutic medicine   25 ( 1 ) 68 - 68  2023年01月  [国際誌]

  　概要を見る

  The proper use of anthracycline-containing regimens in combination with anti-HER2-targeted therapy in a neoadjuvant setting for patients with HER2-positive breast cancer has not been resolved. Regimens preceded by anthracyclines have become the standard of care, and although the order has no significant impact on HER2-negative breast cancer, it is inconclusive as to whether a taxane-first sequence would have a similar effect on HER2-positive breast cancer. The present study aimed to investigate the benefit of a taxane-first sequence and of adriamycin and cyclophosphamide (AC) in patients with non-clinical complete response (non-cCR) to pertuzumab, trastuzumab and docetaxel (PTD). The present single-center prospective observational study was performed to investigate PTD followed by AC, and aimed to clarify the cCR rate after PTD alone and the pathological clinical response (pCR) rate after subsequent AC in patients without cCR after PTD alone. A total 24 patients were analyzed; of these, 14 achieved pCR (pCR rate, 58.3%). While four of 14 patients (28.6%) in the intention-to-treat population achieved pCR, nine of 14 patients (64.3%) achieved pCR with AC but not cCR after PTD. The median tumor reduction rate after four cycles of PTD was 58.9% (range, 20.8-100%) in all 24 patients, whereas the reduction rate after PTD-AC was 76.9% (range, 31.1-100%). Cardiac serious adverse events occurred in three patients (12.5%). In conclusion, a high pCR rate was observed for the taxane-first sequence. Patients were highly responsive to PTD, but some cases achieved additional antitumor effects after AC, which resulted in pCR without cCR after PTD alone. Since cardiotoxicity remains a significant problem, a higher risk-benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN-CTR, date of registration: December 10, 2021.

  DOI PubMed

• Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.

  Kaho Nakamura, Makoto Ishitobi, Chiya Oshiro, Hiroaki Shima, Eriko Takahashi, Takahiro Nakayama, Tadahiko Shien, Kanako Saito, Tsuguo Iwatani, Yukiko Seto, Kaori Terata, Goro Kutomi, Tomoko Ogawa, Hideo Inaji

  In vivo (Athens, Greece)   37 ( 2 ) 794 - 800  2023年  [国際誌]

  　概要を見る

  BACKGROUND/AIM: Currently, several ongoing prospective studies are investigating the safety of breast surgery omission in patients with breast cancer who are exceptional responders to neoadjuvant chemotherapy. However, there is little information about the preferences of these patients regarding omission of breast surgery. PATIENTS AND METHODS: We conducted a questionnaire survey to assess preferences regarding omission of breast surgery among patients with breast cancer who had human epidermal growth factor receptor 2-positive or estrogen receptor-negative tumors and good clinical response after neoadjuvant chemotherapy. Patients' estimation of the risk of ipsilateral breast tumor recurrence (IBTR) after definitive surgery or breast surgery omission was also assessed. RESULTS: Of 93 patients, only 22 (23.7%) said they would omit breast surgery. Under the scenario of omitting breast surgery, the 5-year IBTR rate estimated by patients who said they would omit breast surgery was significantly lower (median, 10%) than the rate estimated by patients who preferred undergoing definitive surgery (median, 30%) (p=0.017). CONCLUSION: The proportion of our surveyed patients who were willing to omit breast surgery was low. Patients who said they preferred to omit breast surgery overestimated the 5-year IBTR risk.

  DOI PubMed

全件表示 >>

Misc 【 表示 ／ 非表示 】

Misc 【 表示 ／ 非表示 】

• 上皮間葉系細胞転換(EMT)促進因子を標的とする新規乳癌治療

  和田朝香, 九冨五郎, 廣橋良彦, 田村保明, 島宏彰, 空閑陽子, 鳥越俊彦, 竹政伊知朗

  日本外科学会定期学術集会(Web)   123rd  2023年

  J-GLOBAL

• 乳癌原発巣と転移を伴うリンパ節,転移を伴わないリンパ節におけるT-cellの分化と分布

  島宏彰, 九冨五郎, 空閑陽子, 和田朝香, 里見蕗乃, 廣橋良彦, 鳥越俊彦, 竹政伊知朗

  日本乳癌学会学術総会プログラム・抄録集   30th (CD-ROM)  2022年

  J-GLOBAL

• hERO1-Lαを標的としたトリプルネガティブ乳癌の新規治療戦略

  和田朝香, 和田朝香, 九冨五郎, 廣橋良彦, 島宏彰, 空閑陽子, 里見蕗乃, 鳥越俊彦, 竹政伊知朗

  日本乳癌学会学術総会プログラム・抄録集   30th (CD-ROM)  2022年

  J-GLOBAL

• hERO1-Lαを標的としたトリプルネガティブ乳癌の新規治療戦略

  和田朝香, 和田朝香, 廣橋良彦, 田村保明, 九冨五郎, 島宏彰, 空閑陽子, 竹政伊知朗, 鳥越俊彦

  日本臨床ストレス応答学会大会抄録集   16th  2022年

  J-GLOBAL

• 乳癌原発巣と転移巣における腫瘍免疫微小環境の病理学的比較検討

  和田朝香, 九冨五郎, 島宏彰, 空閑陽子, 竹政伊知朗, 和田朝香, 廣橋良彦, 鳥越俊彦

  北海道外科雑誌   67 ( 2 )  2022年

  J-GLOBAL

全件表示 >>

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

• トリプルネガティブ乳癌におけるERO1-Lαをターゲットにした複合免疫療法の開発

  基盤研究(C)

  研究期間:

  2020年04月

  -

  2023年03月

   

  九冨 五郎, 島 宏彰, 和田 朝香, 鳥越 俊彦, 廣橋 良彦, 竹政 伊知朗

  　研究概要を見る

  現在Step1は終了し、Step2も概ね終了している。 Step3のSurvivinクローンを用いて、マウスを用いた治療実験の準備中である。マウスをプラセボ群、抗VEGF抗体投与群、抗PD-L1投与群、ERO1阻害剤（ERODOXIN）投与群の5群に分けて実験準備を進めている。 薬剤投与後に腫瘍を摘出して免疫染色を行い、HIF1-α、VEGFーA、PD-L1、ERO1の発現量を調べる。上記治療が腫瘍増殖に与える影響について、腫瘍周囲微小環境に関して評価する。 組織レベルでのCTLの浸潤や血管新生などをそれぞれCD8およびCD31を用いて評価する。また、CD8+ T cellをフローサイトメーターで分離し、エリスポットアッセイにてペプチド特異的CTLが誘導されているかを評価する。ERO1阻害剤に関しては我々が以前使用していたEN460も同時に用いて研究を進めている。